Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

PURPOSE: The hedgehog (Hh) signaling pathway, a key regulator of cell growth and differentiation during development is implicated in pathogenesis of certain cancers. Vismodegib (GDC-0449) is a small-molecule inhibitor of smoothened, a key component of Hh signaling. This phase I trial assessed GDC-04...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: LoRusso, Patricia M., Rudin, Charles M., Reddy, Josina C., Tibes, Raoul, Weiss, Glen J., Borad, Mitesh J., Hann, Christine L., Brahmer, Julie R., Chang, Ilsung, Darbonne, Walter C., Graham, Richard A., Zerivitz, Kenn L., Low, Jennifer A., Von Hoff, Daniel D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5244484/
https://ncbi.nlm.nih.gov/pubmed/21300762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2745
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados